UroGen Pharma Ltd. (URGN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 188.73M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 107.97M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 252.59M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $188.73M | (m) | $107.97M | $252.59M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $189.53M | (m) | $140.27M | $253.69M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $122.21M | (m) | $120.46M | $200.46M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $122.11M | (m) | $127.03M | $185.05M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $122.51M | (m) | $156.95M | $208.72M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $122.11M | (m) | $195.89M | $247.62M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $121.73M | (m) | $236.69M | $285.71M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $121.71M | (m) | $249.57M | $301.94M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $97.81M | (m) | $241.08M | $281.85M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $97.59M | (m) | $164.04M | $200.57M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $98.55M | (m) | $136.97M | $178.31M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $98.52M | (m) | $147.42M | $193.63M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $98.30M | (m) | $47.30M | $95.36M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $97.94M | (m) | $65.05M | $112.95M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $97.54M | (m) | $99.96M | $135.62M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $71.87M | (m) | $95.91M | $128.47M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $71.20M | (m) | $111.74M | $146.14M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $70.80M | (m) | $136.44M | $165.72M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | (m) | $89.14M | $119.75M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |